Key result
taVNS reduces autonomic dysfunction severity by ~57% from baseline in patients with long COVID.
Why the study?
Long COVID is frequently linked to persistent autonomic dysfunction, cognitive impairment, and psychological distress, but effective disease-modifying therapies remain scarce.
Does transcutaneous auricular vagus nerve stimulation improve autonomic symptoms, post-traumatic stress symptoms, and cognitive performance in patients with long COVID?
Does transcutaneous auricular vagus nerve stimulation improve autonomic symptoms, post-traumatic stress symptoms, and cognitive performance in patients with long COVID?
Effect estimate: r 0.867 (95% CI -25.47 ; -13.97)
Absolute Event Rate: 13.78% vs 33.71%
p-value: p=<0.0001
In a pilot study of patients with long COVID, 8 weeks of transcutaneous auricular vagus nerve stimulation significantly improved autonomic, psychological, and cognitive symptoms without adverse events.
May improve autonomic symptoms in long COVID without adverse events; leaves open the need for randomized trials to confirm benefit.
Long COVID is frequently associated with persistent autonomic dysfunction, cognitive impairment, and psychological distress, reflecting sustained neuroimmune and autonomic dysregulation. Effective disease-modifying therapies remain scarce. To evaluate the effects of transcutaneous auricular vagus nerve stimulation (taVNS) on autonomic symptoms, post-traumatic stress symptoms, and cognitive performance in patients with long COVID. In this open-label, single-arm prospective pilot study, seventeen patients with long COVID underwent weekly one-hour taVNS sessions for eight consecutive weeks. Autonomic symptoms were assessed using the Composite Autonomic Symptom Score-31 (COMPASS-31), psychological symptoms using the PTSD Checklist for DSM-5 (PCL-5), and cognitive function using a standardized attention and executive function battery (COGBAT). Outcomes were evaluated at baseline and post-intervention. Paired non-parametric analyses were performed. Following taVNS, autonomic symptoms improved significantly, with mean COMPASS-31 scores decreasing from 33.71 ± 16.81 to 13.78 ± 9.38 (p < 0.0001). Post-traumatic stress symptoms were significantly reduced (PCL-5: 25.76 ± 14.99 to 19.47 ± 14.63; p = 0.028). Cognitive performance improved, with COGBAT scores increasing from 37.71 ± 25.75 to 49.41 ± 26.79 (p = 0.011). No adverse events were reported. taVNS appears to be a safe and promising non-pharmacological intervention for improving autonomic dysfunction, cognitive impairment, and psychological symptoms in long COVID. These findings warrant confirmation in randomized, sham-controlled trials.
No takes yet. Share an insight, caveat, or question.
Azabou et al. (2026) studied Long COVID (n=17). Transcutaneous auricular vagus nerve stimulation (taVNS) vs. Baseline (single-arm study) was evaluated on Composite Autonomic Symptom Score-31 (COMPASS-31) (r 0.867, 95% CI -25.47 ; -13.97, p=<0.0001). Transcutaneous auricular vagus nerve stimulation significantly reduced autonomic dysfunction severity by 56.6% compared to baseline in patients with long COVID.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: